Fennec Pharmaceuticals (FENC) FY 2025 Conference May 20, 2025 03:00 PM ET Speaker0 Hello, and welcome to the latest in our series of fireside chats here at H. C. Wainwright's Bioconnet Conference at NASDAQ. My name is Ram Selvaraju and I'm a Senior Healthcare Equity Research Analyst and Managing Director within Wainwright's Equity Research Department. I'm joined here today by members of the senior executive leadership team at FENEC Pharmaceuticals. FENEC is traded on the NASDAQ under the ticker symbol FENEC ...

Fennec Pharmaceuticals (FENC) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Company Participants Robert Andrade - Chief Financial OfficerJeffrey Hackman - CEO & Member of the Board of DirectorsSudan Loganathan - Managing DirectorRaghuram Selvaraju - Managing Director, Healthcare Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareMichael Okunewitch - Senior Biotechnology Analyst Operator Good morning, ladies and gentlemen, and welcome to FENIC Pharm ...

Fennec Pharmaceuticals (FENC) Q1 2025 Earnings Call May 13, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to FENIC Pharmaceuticals First Quarter twenty twenty five Earnings and Corporate Update Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now, I would like to turn the confere ...

Core Insights - Fennec Pharmaceuticals reported first quarter 2025 total net revenues of $8.8 million, representing an 18% increase year over year from $7.4 million in the first quarter of 2024 [1][5][10] - The company has successfully launched PEDMARQSI in Germany and the United Kingdom, enhancing access to its product for cancer patients at risk of hearing loss [1][6][29] - The revamped Fennec HEARS™ patient support program aims to improve the experience for adolescent and young adult cancer patients [2][6] Financial Results - Net product sales for the first quarter of 2025 were approximately $8.8 million, up from $7.4 million in the same period last year [5][10] - Total revenue for the first quarter was $8.8 million, with no licensing revenue recorded compared to $17.96 million in the first quarter of 2024 [10] - Operating expenses totaled $9.56 million, down from $11.63 million in the previous year, with selling and marketing expenses decreasing to $2.95 million from $5.21 million [11][10] Business Highlights - The company has strengthened its segmentation model and data-driven target lists, leading to the addition of multiple new accounts across academic and community providers [6][7] - The commercial launch of PEDMARQSI in Europe marks a significant step in expanding access to the product [6][29] - Fennec will participate in the ASCO 2025 Annual Meeting and other investor conferences, indicating ongoing engagement with the medical and investment communities [6][4] Upcoming Events - Fennec will host a conference call on May 13, 2025, at 8:30 a.m. ET to discuss its financial results and business updates [1][8] - The Annual General Meeting is scheduled for June 3, 2025, in New York, providing an opportunity for shareholder engagement [6][4]

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, May 13, 2025. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May 13, 2025Tim ...

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig-Hallum Raghuram Selvaraju - H.C. Wainwright Felix Ampomah - Stephens Michael Okunewitch - Maxim Group Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings and Corporate Update Conference Call. At this ti ...